Bank of Nova Scotia Sells 3,275 Shares of Danaher Corporation $DHR

Bank of Nova Scotia lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 1.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 202,353 shares of the conglomerate’s stock after selling 3,275 shares during the period. Bank of Nova Scotia’s holdings in Danaher were worth $38,366,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. PBCay One RSC Ltd bought a new stake in shares of Danaher in the first quarter valued at about $52,917,000. Forefront Analytics LLC raised its holdings in shares of Danaher by 40.8% in the 1st quarter. Forefront Analytics LLC now owns 1,288 shares of the conglomerate’s stock valued at $244,000 after purchasing an additional 373 shares in the last quarter. CI Investments Inc. lifted its position in shares of Danaher by 2.3% in the 1st quarter. CI Investments Inc. now owns 1,181,493 shares of the conglomerate’s stock worth $224,011,000 after purchasing an additional 26,367 shares during the period. Saturna Capital Corp boosted its stake in shares of Danaher by 1.0% during the first quarter. Saturna Capital Corp now owns 7,476 shares of the conglomerate’s stock valued at $1,417,000 after purchasing an additional 72 shares in the last quarter. Finally, Temasek Holdings Private Ltd boosted its stake in shares of Danaher by 7.3% during the first quarter. Temasek Holdings Private Ltd now owns 306,776 shares of the conglomerate’s stock valued at $58,165,000 after purchasing an additional 20,920 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on DHR. Morgan Stanley reduced their price objective on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. The Goldman Sachs Group cut their price target on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Barclays reduced their price target on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Weiss Ratings upgraded Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. Finally, Stifel Nicolaus cut their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Price Performance

Shares of NYSE DHR opened at $191.87 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.52 and a current ratio of 1.65. The company has a market cap of $134.88 billion, a PE ratio of 34.08, a P/E/G ratio of 2.40 and a beta of 0.79. The business has a 50-day simple moving average of $185.64 and a two-hundred day simple moving average of $197.04. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.77 earnings per share. As a group, equities analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a dividend of $0.40 per share. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.8%. Danaher’s dividend payout ratio is presently 28.42%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.